

Idea to IND®

Pharmaceutical Sciences

SRI offers a full suite of pharmaceutical product capabilities from drug formulation through to manufacturing of final drug product under current Good Manufacturing Practices (cGMP) regulations. We also offer all of the analytical chemistry capabilities required to support early formulation activities through to cGMP product release and long-term stability testing. We offer a variety of state-of-the-art techniques for preformulation, formulation, manufacturing and analytical chemistry that can be applied to your particular product development needs.

SRI has more than 30 years of experience solving challenging problems in formulation, drug delivery, manufacturing and analytical chemistry. Our unique capabilities include robotic systems for rapid identification of optimal solvents, in vitro intestinal penetration models; a proven track record in enhancing absorption of poorly bioavailable or short half-life drugs; manufacturing of a range of dosage forms including topical, oral, sterile, and spray-dried formulations; and extensive stability testing conditions. SRI's comprehensive services will help you achieve your goals – from Idea to IND® and beyond.

Learn more

- 2 Preformulation Studies
- 3 Stability Studies
- 4 Dosage Form Manufacturing: R&D, GLP, and cGMP
- 5 Formulation Development
- 6 Alternative Drug Delivery Systems
- 7 Analytical Chemistry



Drug
Discovery

Drug Metabolism,
Pharmacokinetics,
& Toxicology

Pharmaceutical
Sciences

Clinical
Analysis
Laboratory

Clinical
Trials



Preformulation Studies

SRI specializes in conquering “problem” compounds – those with poor solubility, low bioavailability, short half-life, and/or gastric intolerability. We conduct preformulation studies to guide the formulation strategy for your drug candidate. Typical preformulation characterization studies offered include determination of:

- Physicochemical properties
- Aqueous and pH solubility, organic solvent solubility
- Crystallinity by x-ray
- Hygroscopicity and lipophilicity
- pKa, partition coefficients, and tissue distribution coefficients
- Thermal properties (DSC, TGA)
- Moisture content
- Particle size and morphology
- Drug-excipient compatibility

HYSOLVE™ Our high-throughput robotic solubility screening system is based on an SRI-developed database of solvent combinations based on compatibility and miscibility at FDA-acceptable concentration levels. Drug candidates are screened against single, binary, and ternary solvent combinations to identify optimal solubilizing agents or cosolvents that will provide the best compatibility and solubility.

PERMEE-8™ SRI has developed an *in vitro* Ussing system that can estimate drug transport through different sections of the intestine. This information can guide targeted drug delivery approaches and functional excipient selection to develop a product with maximum absorption. While the Ussing system is primarily used to determine absorption through intestinal tissues and thus is useful for development of oral drug delivery formulations, it can be tailored to estimate absorption through other systems such as mucosal cells and skin.

Stability Studies

SRI offers stability storage and testing that adheres to ICH guidelines. Our standard storage conditions include frozen (ultracold and -20°C), refrigerated (5°C), ambient ($25^{\circ}\text{C}/60\% \text{RH}$), intermediate ($30^{\circ}\text{C}/65\% \text{RH}$), and accelerated ($40^{\circ}\text{C}/75\% \text{RH}$). Custom storage conditions and specialized climatic zone considerations can also be accommodated upon request.

In addition to long-term drug substance and drug product stability studies to support ongoing clinical trials, we routinely incorporate short-term stability studies in the evaluation of candidate formulations. We also perform photostability and temperature cycle studies.

Our stability study evaluations are preceded by forced degradation studies to develop sensitive and specific analytical methods so that impurities and degradation products can be tracked and quantified. Our in-house analytical and synthetic chemists can identify impurities through various structure elucidation techniques and synthesize reference standards of the active ingredient and degradation products to support ongoing stability assessments.

To ensure the quality and security of your drug substance and drug products, our stability storage program features:

- Storage units with validated conditions of temperature, humidity, and light (visible and UV)
- Validated computerized system for continuous monitoring of temperature, humidity, and light, with cumulative reports
- Emergency power back-up for chambers and computer monitoring systems
- Local audible alarms and an automatic notification system to 24/7 on-site security personnel with protocols for notifying facility engineers and technical staff
- A double-lock system to access chambers



**** Stability study failures can be prevented or controlled by formulation development.*

Dosage Form Manufacturing: R&D, GLP, and cGMP



SRI's dosage form manufacturing facilities are designed to provide you with a single, high-quality resource for the manufacture and packaging of oral, topical, and parenteral products for nonclinical and clinical studies. These activities are supported by our Quality Control and Quality Assurance Units which inspect, test, and release the products in full compliance with the FDA GLP and cGMP regulations and international regulatory agencies.

Our R&D, GLP, and cGMP facilities and equipment are designed to support early phase development. The low volume batches needed for safety evaluations and early clinical trials present unique challenges, and we are ready to work with you to overcome limited bulk drug supplies and tight turnaround times.

Our extensive collection of equipment provides the capabilities needed to produce R&D, pilot, and clinical-scale batch sizes including:

Liquid/Sterile Dosage Forms

- Sterile liquid filler
- Liquid capsule filler
- Lyophilizer

Solid Dosage Forms

- Capsule filling,
- Capsule bander
- Capsule polisher
- Capsule sorter
- Tablet press

Topical/Transmucosal Dosage Forms

- Semi-solid filler
- Franz diffusion cells
- In-line permeation cells
- Unguator™

Sterile Spray Drying

- Micronization
- Steroids / potent drug

Mixing and Blending

- Liquid mixing bag system
- Planetary mixers
- V-Blenders
- Emulsifiers

Milling

- Low speed mills
- High speed mills

Granulation

- Roller compactor
- Granulator/oscillator
- Extrusion-spheronization
- Fluid-bed granulator

Coating

- Pan coater
- Spray coater

Packaging

- Induction sealer
- Blister pack sealer
- Heat sealer
- Laminated tube sealer
- Vial capper

Sterilization

- Autoclave
- Depyrogenation
- Sterile filtration

Other

- Fiberoptic dynamic dissolution
- DLS particle size analyzer
- Microfluidizers
- Texture analyzer
- Viscometer

Formulation Development

At SRI, we have the experience and expertise to solve challenging formulation and drug delivery problems. We address the cost parameters and regulatory requirements for formulating new drugs, and we look for simple, economical solutions to dosage design challenges. Our staff has extensive industry experience relating to all types of dosage forms and has worked with new chemical entities, OTC products, generic products, and line extensions. Protection of proprietary information is routinely incorporated into our procedures.

Parenteral (Solution, Lyophilized, Nanosuspension)

- Intravenous
- Intramuscular
 - » Rapid Onset Injectables
 - » Long-Acting Injectables (LAI)
- Subcutaneous

Oral (Immediate-release)

- Powder-in-bottle
- Solution/Suspension/Emulsion
- Capsules
- Tablets
- Spray-Dried Dispersion (SDD)
- Self-emulsifying drug delivery system (SEDDS)
- Orally disintegrating tablets

Oral (Sustained-release)

- Extended-release capsules and tablets
- Multi-particulate Systems (MUPS)
- Microspheres

Topical & Transdermal

- Cream
- Gels
- Ointments
- Film/Patch

**** Formulated drug products are more effective than their individual components used singly.*





Alternative Drug Delivery Systems

Drug delivery technologies can modify drug release, absorption, distribution, and elimination profiles to improve product efficacy and safety, as well as patient convenience and compliance. Oral and parenteral are the most common routes of drug delivery, but alternative routes of administration are preferred in many situations. SRI has expertise in the development of these specialized drug delivery systems:

- Buccal Films, Tablets
- Vaginal films, gels, inserts, bioadhesives
- Nasal
- Biodegradable Implants
- Pediatric Dosage Forms
 - » Syrups
 - » Solutions
 - » Suspensions
- Modified Release Dosage forms
- Nanoparticles/Nanosuspension
- Liposomes
- Bioadhesive/Mucoadhesive Topicals

SRI has been working on formulation and delivery approaches to enable currently approved drugs to be delivered in a more economical and practical manner in an approach sometimes referred to as “IV to PO.” We have had great success in reformulating IV drug products into oral dosage forms.

Analytical Chemistry

SRI has state-of-the-art technology and experienced scientists offering a broad range of analytical method development and validation, and quality control analyses of small molecules and biologics. We work closely with drug development scientists in medicinal chemistry, formulations, pharmacokinetics, toxicology, and manufacturing to identify, quantify, and characterize materials to meet R&D needs and be in full compliance with FDA GLP and cGMP requirements. Our analytical team contributes the following:

- Pharmaceutical analysis
 - » Reference standard characterization and Certificate of Analysis
 - » Bulk pharmaceutical ingredients
 - » Excipient testing according to official monographs
 - » Structure elucidation of intermediates, impurities, and degradants
- Methods development and validation
 - » In-house use
 - » Method transfer in and out
 - » Validation levels tailored to phase of development
- Analytical support for preformulation and formulation development
 - » Efficient immediate feedback to formulators
 - » Short-term stability studies
 - » Planning for final product methods
- Dose verification for *in vivo* and *in vitro* GLP studies
 - » Dose concentrations and homogeneity in vehicle media or device
 - » Short-term dose stability under conditions of use
 - » Test article characterization and stability
- Quality control activities and cGMP clinical trial materials
 - » Quarantine, testing, and release or rejection of materials and products
 - » In-process testing
 - » Cleaning validation
 - » Stability studies per ICH guidelines for drug substances and products

SRI International®

SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. SRI International, a research center headquartered in Menlo Park, California, creates world-changing solutions to make people safer, healthier, and more productive.

SRI Biosciences

Toll-Free: 866.451.5998
Tel.: 650.859.3000
Email: biosciences@sri.com
sri.com/biosciences

San Francisco Bay Area (SRI Headquarters)

333 Ravenswood Avenue
Menlo Park, California 94025-3493
Tel.: 650.859.2000

Shenandoah Valley, VA

140 Research Drive
Harrisonburg, VA 22802
Tel: 540.428.6600

Life Sciences Corridor, MI SRI Biosciences Clinical Trial Unit

46701 Commerce Center Drive
Plymouth, MI 48170
Toll-Free: 1.866.451.5998

www.sri.com/biosciences



STAY CONNECTED



SRI International is a registered trademark of SRI International.
All other trademarks are the property of their respective owners.
Copyright 2020 SRI International. All rights reserved. 03/20

